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Small cell lung carcinoma (SCLC) is an aggressive form of lung 
cancer and presently accounts for 20-25% of all lung cancer cases. 
It is characterised by ectopic secretion of various neuropeptides. 
Among these neuropeptides, oxytocin (OT) as well as vasopressin 
(VP), two neurohypophysial hormones, are synthesised and 
secreted by these tumours. Moreover, the oxytocin receptor (OTR) 
is expressed by the malignant cells as the vasopressin receptors 
V1a, V1b/V3, V2 and a variant V2 are. These receptors all belong 
to the super family of G-protein-coupled receptors (GPCR) 
structurally characterized by seven transmembrane domains. A 
study of pharmacological interactions OT and VP have with these 
receptors on SCLC cells demonstrated that OT and VP produce 
increases in cytosolic Ca++ levels in SCLC cells through OTR- and 
V1aR-mediated processes. No activation of the cAMP pathway 
was detected after VP, DDAVP (a V2R agonist), or OT treatment. 
The activation of the MAP kinase cascade was observed when 
SCLC cells were stimulated with OT or VP. Moreover, both 
hormones, from concentrations as low as 10-9M, increase SCLC 
cell growth. When cells are incubated with a mix of OT (10-9M) 
and an OT antagonist (OVTA, 10-9M), the mitogenic effect of OT 
is inhibited. OVTA (10-9M) used alone induces a decrease of SCLC 
cell growth. These data prompt us to conclude that OT as VP act as 
growth factors on SCLC growth through autocrine/paracrine loops. 
Moreover, the mitogenic effect of these peptides could be mediated 
by cross talk between the inositol-Ca++ and the MAP kinase 
cascades. 
